ATTACHMENT A

Claims:

1. (previously presented) A room-temperature stable injectable solution for veterinary use comprising from 0.5 to 30% (w/v) of Carprofen (6-chloro-α-methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen, and from 2.4% to 12% (w/v) of a poloxamer, and water *q.s.* for injection.

2. (previously presented) An injectable aqueous solution according to Claim 1, wherein the Carprofen salt is in the form of an arginine salt.

3. (previously presented) An injectable aqueous solution according to Claim 1, wherein the carprofen salt is in the form of a lysine salt.

4. (currently amended) An injectable aqueous solution according to ~~any one of Claims 1 to 3,~~ Claim 1, wherein Carprofen is present in an amount of from 2.5 to 7.5% (w/v).

5. (currently amended) An injectable aqueous solution according to ~~any one of Claims 1 to 3,~~ Claim 1, wherein Carprofen is present in an amount of from 2.5 to 5% (w/v).

6. (currently amended) An injectable aqueous solution according to ~~any one of Claims 1-5,~~ Claim 1, comprising arginine in an amount of from 1 to 20% (w/v).

7. (previously presented) An injectable aqueous solution according to Claim 1, wherein an organic solvent is present with the poloxamer.

8. (previously presented) An injectable aqueous solution according to Claim 7, wherein the organic solvent is present in the range of 0.5 to 20%(w/v).

9. (previously presented) An injectable aqueous solution according to Claim 1, wherein the poloxamer is $HO(CH_2CH_2O)_x$ $(CCH_3HCH_2O)_y(CH_2CH_2)_zH$ wherein x is 75, y is 30 and z is 75.

10. (previously presented) An injectable aqueous solution for veterinary use according to Claim 1, where the solution is to be employed in treating felines, wherein the lower limit of the range of Carprofen is 0.25%(w/v).

11. (previously presented) An injectable aqueous solution for veterinary use according to Claim 10, comprising arginine in an amount of from 1 to 20%(w/v).

12. (previously presented) A method of producing a room-temperature stable injectable aqueous solution for veterinary use comprising briging together Carprofen or a physiologically acceptable salt thereof, a poloxamer, and adding sufficient water for injection, to provide a solution containing from 0.5 to 30 % (w/v) of Carprofen (6-chloro-α-methyl-carbazole-2-acetic acid) or a physiologically acceptable salt of Carprofen, and from 2.4% to 12% (w/v) of poloxamer.

13. (previously presented) A method according to Claim 12, wherein the ploxamer is is $HO(CH_2CH_2O)_x$ $(CCH_3HCH_2O)_y(CH_2CH_2)_zH$ wherein x is 75, y is 30 and z is 75.

14. (currently amended) A method of producing an injectable aqueous solution according to Claim 12 ~~or Claim 13~~, wherein said method further comprises the inclusion of a preservative.

15. (currently amended) An injectable aqueous solution for veterinary use according to ~~any one of the Examples 1 to 19~~ Example 1 hereinbefore.

16. (previously presented) A method of producing an injectable aqueous solution substantially as described in the Example 1.

17. (new) A method of producing an injectable aqueous solution according to Claim 13, wherein said method further comprises the inclusion of a preservative.